LEXX – lexaria bioscience corp. (US:NASDAQ)

News

Lexaria Bioscience (LEXX) was upgraded by Weiss Ratings from "sell (e+)" to "sell (d-)".
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales [Yahoo! Finance]
Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely [Yahoo! Finance]
Lexaria's Robust Patent Portfolio Continues to Grow [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com